Ballentine Partners LLC bought a new stake in Absci Co. (NASDAQ:ABSI – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,424 shares of the company’s stock, valued at ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...